Pardoprunox

Legal statusLegal status IdentifiersCAS NumberPubChem CIDChemSpiderUNIICompTox Dashboard (EPA)ECHA InfoCard100.206.783 Chemical and physical dataFormulaC₁₂H₁₅N₃O₂Molar mass233.271 g·mol⁻¹3D model (JSmol)

Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.^[1][2][3][1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.^[1]

Pardoprunox acts as a D₂ (pK_i = 8.1) and D₃ receptor (pK_i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT_1A receptor (pK_i = 8.5) full agonist (IA = 100%).^[1][4] It also binds to D₄ (pK_i = 7.8), α₁-adrenergic (pK_i = 7.8), α₂-adrenergic (pK_i = 7.4), and 5-HT₇ receptors (pK_i = 7.2) with lower affinity.^[1][4] Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.^[4][5]

See also

• Aripiprazole
• Bifeprunox

References

Further reading

• Hauser RA, Bronzova J, Sampaio C, et al. (2009). "Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease". European Neurology. 62 (1): 40–8. doi:10.1159/000216839. PMID 19407454. S2CID 39669742.
• Bronzova J, Sampaio C, Hauser RA, et al. (March 2010). "Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease". Movement Disorders. 25 (6): 738–746. doi:10.1002/mds.22948. PMID 20198713. S2CID 206241386.